Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)

About this episode

This episode discusses the OIG's new regulations on pharmaceutical marketing and their implications for cash-paying patients.

Send us Fan Mail On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Special Advisory Bulletin, the government officially opened a "green lane" for direct-to-patient (DTP) drug sales, specifically addressing the rise of cash-pay programs like TrumpRx. In this episode, we break down why the OIG is now prioritizing lower costs over traditional Anti-Kickback Statute (AKS) risks for cash-paying patients—including th...

People in this episode

Host: Darshan Kulkarni

Topics covered

• pharmaceutical marketing
• healthcare policy
• cash-pay programs
• OIG regulations
• drug sales

Keywords

• OIG
• pharmaceutical marketing
• cash-pay programs
• TrumpRx
• Anti-Kickback Statute

Mentioned in this episode

Organizations: HHS Office of Inspector General, TrumpRx

More episodes of DarshanTalks Podcast

• Unlicensed Medical Advice & The Legal Battle Over Character.AI · May 18, 2026 · 15 min
• Sponsoring Cannabis Research · May 6, 2026 · 5 min
• The New Era of Personal Consent Decrees · April 30, 2026 · 8 min
• Why Private Membership Associations Fail FDA Scrutiny · April 16, 2026 · 7 min
• The Hidden Reason Sites are Firing Recruiters · April 11, 2026 · 8 min
• Don’t Let Your PI Walk Away With Your Study · April 10, 2026 · 1 min